全文获取类型
收费全文 | 21419篇 |
免费 | 1697篇 |
国内免费 | 655篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 228篇 |
妇产科学 | 149篇 |
基础医学 | 1066篇 |
口腔科学 | 164篇 |
临床医学 | 1595篇 |
内科学 | 2581篇 |
皮肤病学 | 330篇 |
神经病学 | 1869篇 |
特种医学 | 207篇 |
外国民族医学 | 1篇 |
外科学 | 763篇 |
综合类 | 2299篇 |
一般理论 | 3篇 |
预防医学 | 1234篇 |
眼科学 | 161篇 |
药学 | 9039篇 |
6篇 | |
中国医学 | 1305篇 |
肿瘤学 | 727篇 |
出版年
2024年 | 37篇 |
2023年 | 326篇 |
2022年 | 416篇 |
2021年 | 708篇 |
2020年 | 700篇 |
2019年 | 796篇 |
2018年 | 813篇 |
2017年 | 865篇 |
2016年 | 763篇 |
2015年 | 759篇 |
2014年 | 1528篇 |
2013年 | 2304篇 |
2012年 | 1360篇 |
2011年 | 1489篇 |
2010年 | 1159篇 |
2009年 | 976篇 |
2008年 | 914篇 |
2007年 | 948篇 |
2006年 | 777篇 |
2005年 | 691篇 |
2004年 | 572篇 |
2003年 | 557篇 |
2002年 | 395篇 |
2001年 | 373篇 |
2000年 | 296篇 |
1999年 | 249篇 |
1998年 | 235篇 |
1997年 | 227篇 |
1996年 | 218篇 |
1995年 | 191篇 |
1994年 | 158篇 |
1993年 | 194篇 |
1992年 | 196篇 |
1991年 | 141篇 |
1990年 | 135篇 |
1989年 | 110篇 |
1988年 | 119篇 |
1987年 | 80篇 |
1986年 | 89篇 |
1985年 | 130篇 |
1984年 | 118篇 |
1983年 | 82篇 |
1982年 | 92篇 |
1981年 | 61篇 |
1980年 | 70篇 |
1979年 | 55篇 |
1978年 | 64篇 |
1977年 | 56篇 |
1976年 | 47篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 500 毫秒
11.
12.
我国奶牛养殖规模不断扩大,奶业产值比重逐步提高,给奶牛疫病防治带来巨大压力。奶牛乳房炎及细菌性肺炎等呼吸系统疾病和细菌性肠炎等消化系统疾病最为常见,抗菌药物的使用成为主要防治手段。但抗菌药物的不当使用易使细菌产生耐药性,增加临床治疗的成本和难度,危害我国奶牛产业发展。本文对截至2021年7月我国和美国、英国、日本、欧盟批准用于奶牛的抗菌药物产品进行整理、统计与分析,包括抗菌药物的分类、剂型以及适应证等,旨在为我国奶牛用抗菌药物管理、合理用药和新兽药开发提供参考。 相似文献
13.
14.
《Value in health》2022,25(12):1958-1966
ObjectivesNational health technology assessments (HTAs) across Europe show differences in evidentiary requirements from assessments by the European Medicines Agency (EMA), affecting time to patient access for drugs after marketing authorization. This article analyzes the differences between EMA and HTA bodies’ evidentiary requirements for oncology drugs and provides recommendations on potential further alignment to minimize and optimally manage the remaining differences.MethodsInterviews were performed with representatives and drug assessment experts from EMA and HTA bodies to identify evidentiary requirements for several subdomains and collect recommendations for potentially more efficiently addressing differences. A comparative analysis of acceptability of the evidence by EMA and the HTA bodies and for potential further alignment between both authorities was conducted.ResultsAcceptability of available evidence was higher for EMA than HTA bodies. HTA bodies and EMA were aligned on evidentiary requirements in most cases. The subdomains showing notable differences concerned the acceptance of limitation of the target population and extrapolation of target populations, progression-free survival and (other) surrogate endpoints as outcomes, cross-over designs, short trial duration, and clinical relevance of the effect size. Recommendations for reducing or optimally managing differences included joint early dialogues, joint relative effectiveness assessments, and the use of managed entry agreements.ConclusionsDifferences between assessments of EMA and HTA bodies were identified in important areas of evidentiary requirements. Increased alignment between EMA and HTA bodies is suggested and recommendations for realization are discussed. 相似文献
15.
It is hypothesized that persons who use drugs (PWUD) in Vietnam who are also HIV-positive may face additional challenges in psychosocial outcomes, and these challenges may extend to their family members. In this study, we examined depressive symptoms, stigma, social support, and caregiver burden of HIV-positive PWUD and their family members, compared to the outcomes of HIV-negative PWUD and their family members. Baseline, 3-month, and 6-month assessment data were gathered from 83 PWUD and 83 family members recruited from four communes in Phú Th? Province, Vietnam. For PWUD, although we observed a general decline in overall stigma over time for both groups, HIV-positive PWUD consistently reported significantly higher overall stigma for all three periods. Depressive symptoms among family members in both groups declined over time; however, family members of HIV-positive PWUD reported higher depressive symptoms across all three periods. In addition, family members of HIV-positive PWUD reported lower levels of tangible support across all three periods. Caregiver burden among family members of HIV-positive PWUD increased significantly over time, whereas the reported burden among family members of HIV-negative PWUD remained relatively unchanged. The findings highlight the need for future interventions for PWUD and family members, with targeted and culturally specific strategies to focus on the importance of addressing additional stigma experienced by PWUD who are HIV-positive. Such challenges may have direct negative impact on their family members' depressive symptoms, tangible support, and caregiver burden. 相似文献
16.
《Journal de Mycologie Médicale》2020,30(2):100970
A survey of mycology laboratories for antifungal susceptibility testing (AFST) was undertaken in France in 2018, to better understand the difference in practices between the participating centers and to identify the difficulties they may encounter as well as eventual gaps with published standards and guidelines. The survey captured information from 45 mycology laboratories in France on how they perform AFST (number of strains tested, preferred method, technical and quality aspects, interpretation of the MIC values, reading and interpretation difficulties). Results indicated that 86% of respondents used Etest as AFST method, with a combination of one to seven antifungal agents tested. Most of the participating laboratories used similar technical parameters to perform their AFST method and a large majority used, as recommended, internal and external quality assessments. Almost all the participating mycology laboratories (98%) reported difficulties to interpret the MIC values, especially when no clinical breakpoints are available. The survey highlighted that the current AFST practices in France need homogenization, particularly for MIC reading and interpretation. 相似文献
17.
18.
19.
20.
金晶 《中国继续医学教育》2020,(10):112-115
目的 探索药学干预对喹诺酮类药物应用的影响.方法 选取2016年3月—2017年3月到医院接受喹诺酮类药物治疗的患者进行研究,分为药物干预前、干预后两组,喹诺酮类药物使用过程中采用药学干预的方法 进行护理,对比干预前后喹诺酮类药物的耐药率、不合理用药率和不合理使用情况.结果 药学干预后,喹诺酮类药物对肺炎克雷伯菌、大肠埃希菌和铜绿假单胞菌的耐药率降低,且不合理联合用药、不合理用法用量和用药禁忌等不合理用药率也显著降低,不合理使用情况也在逐渐减少(P<0.05).结论 药学干预对喹诺酮类药物的应用效果显著. 相似文献